Aktienanalyse zu Alpha Tau Medical Ltd (DRTS)DRTSAlpha Tau Medical Ltd

Alpha Tau Medical Ltd is an Israel-based medical technology company engaged in the research, development, and commercialization of innovative cancer treatment technologies. The Company focuses on Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), a platform designed for the treatment of solid tumors through the localized delivery of alpha radiation within tumor tissue. Its technology utilizes radioactive radium-224 sources that release short-range alpha particles intended to damage and destroy cancer cells while limiting exposure to surrounding healthy tissue. The Company conducts activities related to product development, clinical studies, regulatory approval processes, and commercialization. Alpha Tau Medical Ltd serves the oncology sector and carries out its operations directly and through its subsidiary, Healthcare Capital Corp. It operates in the Healthcare sector (SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS industry).

Currently, Alpha Tau Medical Ltd (DRTS) is not a good buy. The stock is trading at $12.29, with a significant recent decline of 14.71% over the last five days and a staggering 19.36% over the last 20 days. The RSI is at a low 13.697, indicating that the stock is oversold. Furthermore, the company has reported increasing losses, with a net income of -45,813,000 USD in Q2 2026 and an EPS of -0.50, which raises concerns about its financial health. The main risk is the ongoing negative earnings trend, with a forward P/E ratio of 0, indicating no expected profitability in the near term. Given these factors, it is advisable to sell rather than buy at this time.